Skip to main content

Table 3 Mean doses to the spared salivary glands and oral cavity by primary tumor site

From: Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control

Tumor site Patients (nb) Ipsilateral PG Contralateral PG Ipsilateral SMG Contralateral SMG OC
   No. of spared glands Mean dose Gy (range) No. of spared glands Mean dose Gy (range) No. of spared glands Mean dose Gy (range) No. of spared glands Mean dose Gy (range) Nb Mean dose Gy (range)
Oral cavity 8 5 31 (29.4-32.5) 8 27.1 (16–31.7) NS NA NS NA NS NA
Oropharynx 31 12 28.6 (25–31.5) 30 27.5 (23.6-32.2) 2 35.5 (33–38) 8 33.8 (29–36.5) 5 34.2 (29.7-38.2)
Hypopharynx 17 9 28.9 (24.4-31.5) 17 27.6 (22.9-34.4) 1 39.6 4 36.1 (28.7-39.5) 9 34.8 (30.5-40)
Larynx 10 9 26.8 (20.7-33.2) 10 25 (19.1-30.1) 1 34.9 3 36.7 (34–39) 9 30.5 (23–39.7)
Nasopharynx 3 2 30.2 (30.4-30) 3 27.8 (26.7-28.7) 1 38 2 33.1 (30.3-35.8) 3 33.5 (29.7-35.2)
Unknown primary 1 1 32.5 1 17.3 NS NA 1 28 1 44.3
  1. Abbreviations: PG parotid gland; SMG submandibular gland; OC oral cavity; NS Non spared; NA Non applicable.